Prevention of sudden death with the implantable defibrillator in hypertrophic cardiomiopathy;Desfibrilador implantable para la prevención de la muerte súbita en la miocardiopatía hipertrófica

Revista Espanola de Cardiologia

Volumn 59, Issue 6, 2006, Pages 527-530

  Maron, Barry J ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACCURACY; CAUSE OF DEATH; CLINICAL FEATURE; DEFIBRILLATION; DEFIBRILLATOR; EDITORIAL; ELECTROCARDIOGRAPHY; GENETIC ANALYSIS; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERNATIONAL COOPERATION; PROBABILITY; PROPHYLAXIS; PUBLICATION; RISK ASSESSMENT; SECONDARY PREVENTION; SUDDEN DEATH;

EID: 33747076062     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13089737     Document Type: Editorial

References (28)

1. Maron BJ, McKenna WJ, Danielson GK, Kappenberg LJ, Kuhn HJ, Seiman CE, et al. American College of Cardiology/European Society of Cardiology Clinical Expert consensus Document on Hypertrophic cardiomyopathy. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2003;42:1687-713.
2. Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA. 2002;287:1308-20.
3. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: Clinical, demographic and pathological profiles. JAMA. 1996;276:199-204.
4. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003; 349:1064-75.
5. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1-8.
6. Maron BJ, Shen W-K, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000; 342:365-73.
7. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al. Termination of malignant ventricular arrhythmias with an implantable defibrillator in human beings. N Engl J Med. 1980;303:322-4.
8. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
9. Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2003;26:1887-96.
10. Jayatilleke I, Doolan A, Ingles J, McGuire M, Booth V, Richard DR, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol. 2004;93:1192-4.
11. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003;14:337-41.
12. Brugada P, Bartholomay E, Mont L, Brugada R, Brugada J. Treatment of Brugada syndrome with an implantable cardioverter defibrillator. En: Antzelevitch C, editor. The Brugada syndrome: from bench to bedside. Malden: Blackwell; 2005. p. 194-201.
13. Nademanee K, Veerakul G, Mower M, Likittanasombat K, Krittayapong R, Bhuripanyo K, et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation. 2003;107:2221-6.
14. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/ dysplasia. Circulation. 2003;108:3084-91.
15. Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James C, et al. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2004;43:1843-52.
16. Hodgkinson KA, Parfrey PS, Bassett AS, Kupprion C, Drenckhahn J, Norman MW, et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol. 2005:45:400-8.
17. Elliott PM, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881-91.
18. Camm AJ, Nisam S. The utilization of the implantable defibrillator: a European enigma. Eur Heart J. 2000;21:1998-2004.
19. Maron BJ. Contemporary considerations for risk stratification, sudden death and prevention in hypertrophic cardiomyopathy. Heart. 2003;89:977-8.
20. Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Álvarez L, Fernández X, et al. Desfibrilador automático en la miocadiopatía hipertrófica. Experiencia de 3 centros. Rev Esp Cardiol. 2006; 59:537:44.
21. Maron BJ, Estes M, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 2003;107: 2872-5.
22. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ, et al. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-85.
23. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044-51.
24. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart. 1998;79:331-6.
25. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:2195-303.
26. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Mayes DL, Hlatkg MA, et al. ACC/AHA/NASPE 2002 guidelines update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2002;106:2145-61.
27. Maron BJ, Spirito P, Haas TS, for the ICD in HCM Investigators. Efficacy of the implantable defibrillator for prevention of sudden death in hypertrophic cardiomyopathy: data from the international registry of 506 high risk patients [abstract]. Circulation. 2005; 112 Suppl:II-531.
28. Boriani G, Maron BJ, Shen W-K, Spirito P. Prevention of sudden death in hypertrophic cardiomyopathy: But which defibrillator for which patient? Circulation. 2004;110:e438-42.